Autres langues Prothena Corporation plc

Actions

PRTA

IE00B91XRN20

Temps réel estimé Cboe BZX Autres places de cotation 16:47:40 16/07/2024			Varia. 5j.	Varia. 1 janv.
23,49 ^USD	+3,98 %		+12,52 %	-36,19 %

28/05	Prothena recevra 80 millions de dollars de Bristol-Myers Squibb pour la licence mondiale du PRX019	MT
28/05	Prothena annonce que Bristol Myers Squibb a opté pour une licence mondiale exclusive pour PRX019, le deuxième programme de la collaboration mondiale en recherche et développement dans le domaine des neurosciences	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Prothena Corporation plc(NasdaqGS:PRTA) added to Russell Small Cap Comp Value Index	01/07
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 2500 Value Index	01/07
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 3000 Value Index	01/07
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 2000 Value Index	01/07
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 3000E Value Index	01/07
Prothena : Corporate Overview	29/05
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	28/05
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	28/05
Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	28/05
Prothena: Q1 Earnings Snapshot	08/05
Prothena : Corporate Overview	08/05
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $50,000	08/05
Prothena Reports First Quarter 2024 Financial Results and Business Highlights	08/05
Prothena Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Prothena to Report First Quarter 2024 Financial Results on May 8	01/05
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia and Lymphoma	16/04
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma	15/04
Prothena : Director's Report and Financial Statements for Fiscal Year 2023	29/03
Prothena to Participate in Upcoming Healthcare Conferences	05/03
Prothena Names David Ford as Chief People Officer	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Prothena Corporation plc

Actions

PRTA

IE00B91XRN20

Autres langues

Filtres